Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-10-16 Share Issue/Capital Cha…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
(1) PROPOSED ADOPTION OF THE 2022 A SHARE INCENTIVE SCHEME (2) PROPOSED ADOPTION OF THE ASSESSMENT MANAGEMENT MEASURES (3) PROPOSED ISSUE AND GRANT OF NEW A SHARES UNDER THE 2022 A SHARE INCENTIVE SCH
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the proposed adoption of a 2022 A Share Incentive Scheme by RemeGen Co., Ltd. It details the purpose, structure, participants, number of shares to be granted, grant price, and other terms related to the incentive scheme. The text is focused on the proposal and approval process for a share incentive plan, including the issue and grant of new shares under a specific mandate. There is no financial performance data, audit information, or detailed financial statements. The document is not a full report but an announcement of a corporate action related to share incentives and capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues and related capital changes.
2022-10-16 English
VOLUNTARY ANNOUNCEMENT - TELITACICEPT RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR TREATMENT OF MYASTHENIA GRAVIS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the FDA granting orphan drug designation for their drug telitacicept for the treatment of myasthenia gravis. It contains no financial data, no detailed financial statements, no regulatory certifications, or voting results. It is a corporate announcement about a regulatory milestone related to drug development. The document length is 4135 characters, which is relatively short and reads as an announcement rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other financial or governance report. It is not a regulatory filing in the sense of compliance or officer certification, nor is it a report publication announcement. The content fits best under a general regulatory or corporate announcement category. Given the available categories, the closest fit is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-10-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized/registered share capital and issued shares for RemeGen Co., Ltd. It includes confirmations related to share issuance and compliance with listing rules. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content is focused on share capital and share issuance movements, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2022-10-07 English
PROPOSED MANDATE FOR POTENTIAL VERY SUBSTANTIAL DISPOSAL INVOLVING DISPOSAL OF PARTIAL INTERESTS IN SHOUCHI ENTERPRISE THROUGH PUBLIC TENDER
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed mandate for a very substantial disposal involving the disposal of partial interests in a subsidiary company through a public tender. It discusses the details of the proposed disposal, listing rules implications, procedures, consideration, and conditions precedent. The document is lengthy (15,000 characters) and contains detailed information about the transaction but does not contain financial statements or comprehensive financial performance data. It is clearly an announcement of a significant corporate transaction related to disposal of assets and seeking shareholder approval. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including disposals of significant assets or equity interests. It is not a full annual or interim report, nor a merger/acquisition filing, but a disposal announcement requiring shareholder mandate. Therefore, the appropriate classification is CAP with high confidence.
2022-10-06 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 30 September 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, for Overseas Chinese Town (Asia) Holdings Limited. It includes confirmations related to share issuance and compliance with listing rules on the Hong Kong Stock Exchange. The document is structured as a regulatory submission with no financial statements or management discussion. It is not an annual or interim report, earnings release, or any form of shareholder meeting material. It is a regulatory filing reporting share capital movements and confirmations to the exchange, fitting the definition of a Regulatory Filing (RNS). The document length (6229 characters) and content confirm it is a substantive regulatory report rather than a brief announcement or certification only.
2022-10-05 English
INSIDE INFORMATION - POTENTIAL DISPOSAL OF PARTIAL INTERESTS IN A SUBSIDIARY THROUGH PUBLIC TENDER
Capital/Financing Update Classification · 95% confidence The document is an announcement by Overseas Chinese Town (Asia) Holdings Limited regarding a potential disposal of partial interests in a subsidiary through a public tender. It references regulatory rules (Listing Rules, Securities and Futures Ordinance) and describes the potential transaction and its regulatory implications. The document does not contain financial statements or detailed financial data, nor is it a transcript, report, or presentation. It is a formal announcement about a potential capital transaction (disposal of equity interests) and the process involved. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is about a potential disposal of a significant equity interest, which is a capital structure change. The length and content confirm it is not a brief notice or a report publication announcement but a substantive announcement about a financing-related event.
2022-09-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.